In phase III trials, all agents that inhibit IL-13, specifically dupilumab, tralokinumab, lebrikizumab, cendakimab, and eblasakimab, have been reported to have a considerably increased risk of conjunctivitis, injection site reactions, and head and neck erythema. This evidence concerns the gene IL13 and conjunctivitis.